UnitedHealth

[seanismorris]

DexCom (DXCM +3.5%) is up on average volume on the heels of its announcement of a partnership with UnitedHealth Group (UNH +3%) aimed at using continuous glucose monitoring (CGM) in an integrated effort to manage patients with type 2 diabetes in a more cost-effective way.

Specifically, UNH plans to use CGM data in addition to a patient's diet and exercise activity with the aim of modifying the patient's behavior to better manage blood sugar levels. Significant cost savings are likely if the patient is able to alter their lifestyle (better diet, more exercise) and avoid transitioning to more expensive drugs.

The partnership will start with a 10K-subject study that will roll out over the next six-to-nine months. If successful, UNH will implement a network-wide initiative over the following several years.

The type 2 space is much larger that type 1 so a successful program would bode well for DexCom's CGM system.

——-x—-x————x-

Well done Dexcom!  Can MannKind do the same with Afrezza?

[dreamboatcruise]

Wish I bought more DXCM than I did when they had weakness on Libre US approval.

[centralcoastinvestor]

Is that a mannmade sighting I just saw on this thread?  It was only a "like" but I believe that counts.  

[mannmade]

Yes indeed CCI, after a bit of a hiatus I am back on a regular basis following the Board and Mannkind. I have been quietly keeping on top of the story through regular contact with Sports and Baba. Have been accumulating on the recent dips, as I feel like many, the worst is over although still a ways to go... Am cautiously optimistic that Mannkind will see progress this coming 2018 sufficient to finally get the recognition it deserves from the medical community. GLTAL's!

[centralcoastinvestor]

Nov 29, 2017 14:25:36 GMT -5 mannmade said:

Yes indeed CCI, after a bit of a hiatus I am back on a regular basis following the Board and Mannkind. I have been quietly keeping on top of the story through regular contact with Sports and Baba. Have been accumulating on the recent dips, as I feel like many, the worst is over although still a ways to go... Am cautiously optimistic that Mannkind will see progress this coming 2018 sufficient to finally get the recognition it deserves from the medical community. GLTAL's!

Welcome back. 

[mannmade]

Thank you...

[sayhey24]

Lets hope Mike figured out a way to get afrezza into this. They are saying the partnership will start with a 10K-subject study that will roll out over the next six-to-nine months. They are hoping for significant cost savings if the patient is able to alter their lifestyle (better diet, more exercise) and avoid transitioning to more expensive drugs.

Prior studies have show about 50% can slow or stop the progression. However early insulin intervention have shown better results.

It would be IMO in the best interests of United Health to see one arm include afrezza for the first 3 to 6 months in addition to the exercise/diet and compare the results to the exercise only arm.